vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and Northfield Bancorp, Inc. (NFBK). Click either name above to swap in a different company.
Northfield Bancorp, Inc. is the larger business by last-quarter revenue ($41.3M vs $37.2M, roughly 1.1× GYRE THERAPEUTICS, INC.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -1545.5%, a 1541.8% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 12.7%). Northfield Bancorp, Inc. produced more free cash flow last quarter ($52.5M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 15.0%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
Northfield Bancorp, Inc. is a regional bank holding company based in the United States, operating primarily across the U.S. Northeast region. It provides a full range of personal and commercial banking services including deposit accounts, mortgage loans, commercial lending, and wealth management solutions for retail consumers, small to medium-sized businesses and local community clients.
GYRE vs NFBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $41.3M |
| Net Profit | $-1.4M | $-27.4M |
| Gross Margin | 95.3% | — |
| Operating Margin | 0.3% | -1263.3% |
| Net Margin | -3.7% | -1545.5% |
| Revenue YoY | 33.4% | 12.7% |
| Net Profit YoY | -340.1% | -343.6% |
| EPS (diluted) | $-0.01 | $-0.68 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $41.3M | ||
| Q3 25 | $30.6M | $39.2M | ||
| Q2 25 | $26.8M | $38.9M | ||
| Q1 25 | $22.1M | $34.8M | ||
| Q4 24 | $27.9M | $36.7M | ||
| Q3 24 | $25.5M | $31.8M | ||
| Q2 24 | $25.2M | $31.5M | ||
| Q1 24 | $27.2M | $31.3M |
| Q4 25 | $-1.4M | $-27.4M | ||
| Q3 25 | $5.9M | $10.8M | ||
| Q2 25 | $1.6M | $9.6M | ||
| Q1 25 | $3.7M | $7.9M | ||
| Q4 24 | $569.0K | $11.3M | ||
| Q3 24 | $2.9M | $6.5M | ||
| Q2 24 | $4.5M | $6.0M | ||
| Q1 24 | $9.9M | $6.2M |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
| Q4 25 | 0.3% | -1263.3% | ||
| Q3 25 | 22.7% | 37.7% | ||
| Q2 25 | 8.1% | 35.6% | ||
| Q1 25 | 10.3% | 31.0% | ||
| Q4 24 | 2.4% | 38.0% | ||
| Q3 24 | 16.6% | 27.9% | ||
| Q2 24 | 12.7% | 29.1% | ||
| Q1 24 | 29.7% | 27.2% |
| Q4 25 | -3.7% | -1545.5% | ||
| Q3 25 | 19.4% | 27.4% | ||
| Q2 25 | 5.9% | 24.6% | ||
| Q1 25 | 16.9% | 22.6% | ||
| Q4 24 | 2.0% | 30.7% | ||
| Q3 24 | 11.2% | 20.5% | ||
| Q2 24 | 18.0% | 18.9% | ||
| Q1 24 | 36.6% | 19.9% |
| Q4 25 | $-0.01 | $-0.68 | ||
| Q3 25 | $0.03 | $0.27 | ||
| Q2 25 | $0.00 | $0.24 | ||
| Q1 25 | $0.00 | $0.19 | ||
| Q4 24 | $0.00 | $0.27 | ||
| Q3 24 | $0.01 | $0.16 | ||
| Q2 24 | $0.01 | $0.14 | ||
| Q1 24 | $0.03 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $164.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.0M | $690.1M |
| Total Assets | $166.1M | $5.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | $164.0M | ||
| Q3 25 | $60.0M | $131.7M | ||
| Q2 25 | $54.4M | $97.6M | ||
| Q1 25 | $29.9M | $101.7M | ||
| Q4 24 | $26.7M | $167.7M | ||
| Q3 24 | $25.1M | $232.9M | ||
| Q2 24 | $25.1M | $153.5M | ||
| Q1 24 | $37.4M | $238.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $666.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $106.0M | $690.1M | ||
| Q3 25 | $101.9M | $719.6M | ||
| Q2 25 | $92.0M | $710.3M | ||
| Q1 25 | $68.1M | $711.1M | ||
| Q4 24 | $63.3M | $704.7M | ||
| Q3 24 | $63.2M | $699.6M | ||
| Q2 24 | $60.4M | $693.0M | ||
| Q1 24 | $56.6M | $698.4M |
| Q4 25 | $166.1M | $5.8B | ||
| Q3 25 | $159.4M | $5.7B | ||
| Q2 25 | $152.6M | $5.7B | ||
| Q1 25 | $129.8M | $5.7B | ||
| Q4 24 | $125.4M | $5.7B | ||
| Q3 24 | $125.2M | $5.7B | ||
| Q2 24 | $120.9M | $5.7B | ||
| Q1 24 | $122.0M | $5.9B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.95× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $53.7M |
| Free Cash FlowOCF − Capex | $-5.8M | $52.5M |
| FCF MarginFCF / Revenue | -15.5% | 127.1% |
| Capex IntensityCapex / Revenue | 0.4% | 2.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $89.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $53.7M | ||
| Q3 25 | $4.7M | $13.9M | ||
| Q2 25 | $2.1M | $14.1M | ||
| Q1 25 | $-129.0K | $9.4M | ||
| Q4 24 | $-2.8M | $31.1M | ||
| Q3 24 | $1.7M | $14.0M | ||
| Q2 24 | $-5.5M | $6.9M | ||
| Q1 24 | $2.9M | $4.2M |
| Q4 25 | $-5.8M | $52.5M | ||
| Q3 25 | $4.0M | $13.6M | ||
| Q2 25 | $1.8M | $13.9M | ||
| Q1 25 | $-251.0K | $9.2M | ||
| Q4 24 | $-2.8M | $30.0M | ||
| Q3 24 | $1.0M | $13.7M | ||
| Q2 24 | $-6.9M | $6.7M | ||
| Q1 24 | $2.7M | $3.8M |
| Q4 25 | -15.5% | 127.1% | ||
| Q3 25 | 13.1% | 34.6% | ||
| Q2 25 | 6.8% | 35.7% | ||
| Q1 25 | -1.1% | 26.3% | ||
| Q4 24 | -10.1% | 81.6% | ||
| Q3 24 | 4.1% | 43.2% | ||
| Q2 24 | -27.5% | 21.1% | ||
| Q1 24 | 9.8% | 12.1% |
| Q4 25 | 0.4% | 2.8% | ||
| Q3 25 | 2.2% | 0.8% | ||
| Q2 25 | 1.0% | 0.6% | ||
| Q1 25 | 0.6% | 0.7% | ||
| Q4 24 | 0.2% | 3.1% | ||
| Q3 24 | 2.7% | 0.7% | ||
| Q2 24 | 5.8% | 0.8% | ||
| Q1 24 | 0.9% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | 1.29× | ||
| Q2 25 | 1.32× | 1.48× | ||
| Q1 25 | -0.03× | 1.20× | ||
| Q4 24 | -4.85× | 2.76× | ||
| Q3 24 | 0.60× | 2.14× | ||
| Q2 24 | -1.21× | 1.16× | ||
| Q1 24 | 0.29× | 0.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
